The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Athie-Morales, V.
Right arrow Articles by Hilkens, C. M. U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Athie-Morales, V.
Right arrow Articles by Hilkens, C. M. U.
The Journal of Immunology, 2004, 172: 61-69.
Copyright © 2004 by The American Association of Immunologists

Sustained IL-12 Signaling Is Required for Th1 Development 1

Veronica Athie-Morales2,*, Hermelijn H. Smits{ddagger}, Doreen A. Cantrell3,* and Catharien M. U. Hilkens4,{dagger}

* Lymphocyte Activation Laboratory and {dagger} Biochemical Regulatory Mechanisms Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom; and {ddagger} Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

STAT4 is an essential transcription factor for Th1 cell development. IL-12 and IFN-{alpha} both activate STAT4, but with different kinetics. In this study we compared their capacities to drive differentiation of human naive Th cells toward the Th1 phenotype. The Th1-polarizing activity of IFN-{alpha} was much weaker than that of IL-12, correlating with a marked difference in the kinetics of STAT4 activation; the response to IL-12 was sustained (>48 h), whereas the response to IFN-{alpha} was transient (4 h). The continuous presence of IL-12 was required for sustained STAT4 activation. Similarly, optimal Th1 polarization was only achieved upon prolonged exposure to IL-12 and could not be induced by a transient IL-12 pulse. Furthermore, the cytokine IL-2 potentiated sustained IL-12/STAT4 responses through up-regulation of IL-12R expression and synergized with IL-12 in driving Th1 cell development. Transient IFN-{alpha} responses, on the other hand, were not prolonged by IL-2. IFN-{alpha} treatment induced down-regulation of IFN-{alpha}{beta} receptor subunit 1, rendering cells refractory to IFN-{alpha}, but did not trans-inhibit the IL-12/STAT4 response. These data indicate that sustained IL-12 signaling is essential for optimal Th1 cell development and that transient activation of STAT4 in response to IFN-{alpha} may explain the poor Th1-polarizing capacity of this cytokine. Collectively these data show that the duration of cytokine signaling is important for determining the biological response.


Related articles in The JI:

IN THIS ISSUE

The JI 2004 172: 1-2. [Full Text]  



This article has been cited by other articles:


Home page
J. Immunol.Home page
A. M. Davis, K. A. Hagan, L. A. Matthews, G. Bajwa, M. A. Gill, M. Gale Jr., and J. D. Farrar
Blockade of Virus Infection by Human CD4+ T Cells via a Cytokine Relay Network
J. Immunol., May 15, 2008; 180(10): 6923 - 6932.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
V. Athie-Morales, G. M. O'Connor, and C. M. Gardiner
Activation of Human NK Cells by the Bacterial Pathogen-Associated Molecular Pattern Muramyl Dipeptide
J. Immunol., March 15, 2008; 180(6): 4082 - 4089.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. J. Ramos, A. M. Davis, T. C. George, and J. D. Farrar
IFN-{alpha} Is Not Sufficient to Drive Th1 Development Due to Lack of Stable T-bet Expression
J. Immunol., September 15, 2007; 179(6): 3792 - 3803.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. A. Byrnes, D.-Y. Li, K. Park, D. Thompson, C. Mocilnikar, P. Mohan, J. P. Molleston, M. Narkewicz, H. Zhou, S. F. Wolf, et al.
Modulation of the IL-12/IFN-{gamma} axis by IFN-{alpha} therapy for hepatitis C
J. Leukoc. Biol., March 1, 2007; 81(3): 825 - 834.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
A. O. Abdalla, L. Hansson, I. Eriksson, B. Nasman-Glaser, E. D. Rossmann, H. Rabbani, H. Mellstedt, and A. Osterborg
Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma - evaluation of T-cell responses by different read-out systems
Haematologica, January 1, 2007; 92(1): 110 - 114.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. S. Berenson, M. Gavrieli, J. D. Farrar, T. L. Murphy, and K. M. Murphy
Distinct Characteristics of Murine STAT4 Activation in Response to IL-12 and IFN-{alpha}
J. Immunol., October 15, 2006; 177(8): 5195 - 5203.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. J. Fahey, R. A. Robins, K. B. Kindle, D. M. Heery, and C. S. Constantinescu
Effects of glucocorticoids on STAT4 activation in human T cells are stimulus-dependent
J. Leukoc. Biol., July 1, 2006; 80(1): 133 - 144.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. N. MacGregor, Q. Li, A. E. Chang, T. M. Braun, D. P.M. Hughes, and K. T. McDonagh
Ex vivo Culture with Interleukin (IL)-12 Improves CD8+ T-Cell Adoptive Immunotherapy for Murine Leukemia Independent of IL-18 or IFN-{gamma} but Requires Perforin.
Cancer Res., May 1, 2006; 66(9): 4913 - 4921.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. K. De, C. L. Miller-Graziano, S. E. Calvano, K. Laudanski, S. F. Lowry, L. L. Moldawer, D. G. Remick Jr, N. Rajicic, D. Schoenfeld, and R. G. Tompkins
Selective Activation of Peripheral Blood T Cell Subsets by Endotoxin Infusion in Healthy Human Subjects Corresponds to Differential Chemokine Activation
J. Immunol., November 1, 2005; 175(9): 6155 - 6162.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.